View in EDS HTML Full Text PDF Full Text

Precision Medicine in Non-Hodgkin Lymphoma: Advances in BTK Inhibition, CD30-Directed Antibody–Drug Conjugates, and HDAC-Mediated Epigenetic Therapy with Pirtobrutinib, Brentuximab Vedotin, and Belinostat.

Saved in:
Bibliographic Details
Title: Precision Medicine in Non-Hodgkin Lymphoma: Advances in BTK Inhibition, CD30-Directed Antibody–Drug Conjugates, and HDAC-Mediated Epigenetic Therapy with Pirtobrutinib, Brentuximab Vedotin, and Belinostat.
Authors: Kawczak, Piotr1 (AUTHOR) piotr.kawczak@gumed.edu.pl, Bączek, Tomasz1,2 (AUTHOR)
Source: Journal of Clinical Medicine. Jun2026, Vol. 15 Issue 12, p4425. 45p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:20770383
DOI:10.3390/jcm15124425